They had been going to couples therapy for eighteen months. Weekly. Homework between sessions. Scheduled date nights that both of them approached like a work meeting neither wanted to attend. She sat in that room again and again trying to find the feeling she was supposed to have and could not locate it anywhere in her body. She was 47. Her husband had started asking, gently, whether she still wanted to be married. She did not know how to say that she wanted him and simultaneously felt nothing, because those two things should not be able to be true at once.
Nobody, in eighteen months, had run a hormone panel. Nobody had asked whether she was in perimenopause.
She is the reason I write about this topic even though it is the one that takes the most courage to publish. When she told me her story, the sentence that stayed with me was not about her marriage. It was this: “I thought I had stopped loving him and I was too ashamed to say it out loud.” She had spent a year and a half interrogating her feelings for her husband when what had actually changed was her endocrine system. That is not a communication breakdown. That is a diagnostic failure, and she paid for it in a currency no clinician was tracking.
Declining sexual desire in perimenopause is not a relationship problem wearing a medical costume. It is a physiological event with four measurable hormonal drivers and an established evidence base for treatment. Treating the relationship when the body needs treatment is not gentle. It is a failure of clinical clarity, and it teaches a woman to distrust her own feelings about the person she loves.
Four hormones change at once, and all four touch desire
Sexual desire is not produced by one hormone. It runs on at least four, and in perimenopause all four are moving at the same time.
Estradiol, the main form of estrogen your body produces, maintains genital blood flow and tissue responsiveness. When it falls, physical arousal becomes harder to reach and less intense when it arrives. Testosterone, which women produce in smaller amounts than men but depend on significantly, drives the dopamine reward pathways that generate wanting rather than just responding. Progesterone influences the calm, receptive state that desire tends to emerge from. DHEA, a precursor hormone your adrenal glands produce that your body converts into both estrogen and testosterone, declines steadily from your thirties onward.
Four systems, all shifting, all feeding into the same experience from different directions. This is why the change so often feels total rather than partial. It is not one input dimming. It is four.
Stress suppresses testosterone through a specific pathway, not a vague one
Here is where the advice most women receive becomes actively misleading. She gets told her libido is low because she is stressed, and she hears that as: this is in your head, manage it better.
The relationship between stress and desire is mechanical. Chronic cortisol elevation increases production of sex hormone binding globulin, a protein made by your liver that binds to testosterone in your bloodstream. Testosterone bound to this protein is not biologically available to your tissues. So the stress does not dampen desire metaphorically. It removes usable testosterone from circulation through a measurable pathway.
This distinction matters for what happens next. A standard blood panel measuring total testosterone can look unremarkable while the bioavailable fraction is meaningfully low. If you have this conversation, the specific ask is for total testosterone alongside sex hormone binding globulin, so the two can be read together. Most women are never told to ask for the second one.
There is a treatment with the highest grade of evidence, and most women have never been offered it
In 2019, an international task force convened by the International Menopause Society published the Global Consensus Position Statement on the Use of Testosterone Therapy for Women, endorsed by eleven international medical societies including the Endocrine Society. Its conclusion on testosterone therapy for women in menopause with hypoactive sexual desire disorder, the clinical term for low desire that causes personal distress, was rated Level I, Grade A. That is the strongest evidence classification available.
The statement found that testosterone at doses approximating normal premenopausal levels improves sexual desire, arousal, orgasmic function, and pleasure, and reduces sexual distress, above the effects of placebo.
Now set that against how common this is. Low sexual desire affects 26.7% of women before the transition and rises to 52.4% of women who have reached menopause naturally, according to a nationally representative US study of over 2,200 women. Hypoactive sexual desire disorder peaks precisely in midlife, affecting 12.3% of women aged 45 to 64 compared with 7.4% of women over 65. And in a clinic-based study across twenty US sites, only 53% of women who met the diagnostic criteria had ever raised it with a health professional at all.
A condition that peaks in midlife, has Level I Grade A treatment evidence, and reaches roughly half of women in menopause. Barely half of the women who have it have ever mentioned it in a medical setting.
Go back to the woman in the couples therapy room. Her marriage was never the problem. When she finally had a hormone panel run and a conversation about what four simultaneous hormonal changes do to desire, the relief she described was not primarily about treatment options. It was about no longer believing she had fallen out of love with her husband.
Eighteen months of interrogating a feeling that was never the real variable. That is the cost of treating a physiological event as a relational one.
Here is the landing. If your desire has changed in perimenopause, the first question is not what is wrong with your relationship. It is what is happening to your hormones, and nobody can answer that without measuring.
The action this week is specific. At your next appointment, ask for total testosterone measured alongside sex hormone binding globulin, and ask for your estradiol and DHEA to be looked at in the same picture rather than one at a time. Then ask the question that changes the frame: given these results, are we looking at a hormonal driver here, and what are my options if we are?
That question is why I built the free assessment at EmpressHealth.ai. Not to replace the appointment, but so you arrive holding your own pattern and the vocabulary to describe it.
You have not stopped wanting your life. Your chemistry changed, and nobody measured it. There is a difference, and it belongs to you now.